Mr. Erez Tetro reports

VVT MED CLOSES $1,065,664 FIRST TRANCHE OF PRIVATE PLACEMENT OF UNITS

On April 21, 2026, VVT Med Inc. completed the first tranche of its previously announced non-brokered private placement offering for up to gross proceeds of $3-million, issuing 4,262,654 units at a price of 25 cents per unit for gross proceeds of $1,065,663.50.

Each unit consists of one common share of the company and one-half of one common share purchase warrant. Each whole warrant is exercisable into one common share at an exercise price of 37.5 cents per warrant share for a period of 24 months from the date of issuance.

The net proceeds from the offering will be used to support expanded U.S. and global commercialization efforts, product manufacturing to accommodate anticipated demand, working capital and general corporate purposes. The securities issued pursuant to the offering will be subject to a four-month hold period from the date of issuance in accordance with applicable securities laws and the policies of the TSX Venture Exchange. The company anticipates closing a second tranche of the offering in due course.

In connection with the offering, the company paid certain eligible finders a cash fee of up to 8 per cent of the gross proceeds raised in respect of the offering from subscribers introduced by such finders to the company, for a total of $27,800. In addition, the company issued to eligible finders such number of finder warrants equal to 8 per cent of the number of units sold under the offering to subscribers introduced by such finders to the company, for a total of 111,200 finder warrants. Each finder warrant will entitle the holder to acquire one common share at an exercise price of 37.5 cents per share for a period of 24 months following the date of issuance.

Insiders of the company acquired an aggregate of 1,731,819 units under the offering. As such, this participation constitutes a related party transaction as defined under Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions. The company has relied on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(1)(a), respectively, of MI 61-101 in respect of such insider participation. The company did not file a material change report 21 days prior to the closing date of the offering as details of the respective participation of such insiders in the offering were unknown at such time.

The offering is subject to receipt of all necessary regulatory approvals, including the final approval of the TSX-V.

Early warning reporting

Michal Tisser acquired 1,731,819 common shares and 865,910 warrants under the offering. Immediately prior to the completion of the offering, Mr. Tisser owned or exercised control or direction over 5,312,179 common shares and 2,081,984 common share purchase warrants, representing 7.79 per cent and 10.84 per cent of the outstanding common shares of the company on an undiluted and partially diluted basis, respectively. After completion of the offering, Mr. Tisser owns or exercises control or direction over 7,043,998 common shares and 2,947,894 common share purchase warrants, representing 9.72 per cent and 13.78 per cent of the outstanding common shares of the company on an undiluted and partially diluted basis, respectively.

The acquisition of the securities described above was completed for investment purposes. Depending on the market and other conditions, Mr. Tisser may, from time to time, in the future, increase or decrease the ownership, control or direction over securities of the company, through market transactions, private agreements or otherwise.

In satisfaction of the requirements of Multilateral Instrument 62-104, Take-Over Bids and Issuer Bids, and National Instrument 62-103, The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, an early warning report respecting the acquisition of securities by Mr. Tisser will be filed under the company's SEDAR+ profile. To obtain a copy of the early warning report filed by Mr. Tisser, please contact the company at erez@vvtmed.com or refer to SEDAR+ under the company's profile.

About VVT Med Inc.

VVT is the only FDA-cleared (U.S. Food and Drug Administration), stand-alone company offering non-thermal, non-tumescent (NT-NT) varicose vein treatment technology. VVT's catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia or downtime. Addressing the widest range of vein diameters, VVT's solutions empower physicians to treat both the medical and aesthetic aspects of vein disease through a cost-efficient, simultaneous sclerosant injection and blood aspiration process. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

We seek Safe Harbor.